US-based medical device company BioVentrix has reported the first clinical application of its closed-chest Revivent TC TransCatheter Ventricular Enhancement System in The Netherlands.
Designed for the less invasive ventricular enhancement (LIVE) procedure, the Revivent TC System serves as an alternative to conventional surgical ventricular restoration (SVR), by enabling a closed-chest approach.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Revivent TC System is placed without sternotomy or ventriculotomy, thereby eliminating the need for cardiopulmonary bypass.
Its proprietary transcatheter delivery system enables volume reduction of the left ventricle (LV) through placement of anchors designed to exclude scarred myocardial tissue from the left ventricle while also restoring its more natural conical shape.
The Revivent TC System uses a hybrid endovascular technique performed in the hybrid cath lab which allows treatment of fragile patient population by eliminating the risks of open surgical intervention.
During the procedure conducted in The Netherlands, the device was successfully implanted using four micro-anchor pairs in a 56-year-old male patient suffering from ischemic heart failure.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe procedure reshaped the left ventricle and decreased the left ventricular end systolic volume index (LVESVI).
St Antonius Hospital in Nieuwegein, The Netherlands interventional cardiologist Dr Pierfrancesco Agostoni said: "We achieved a sizeable reduction in the patient's left ventricular volume and he will see significant improvement in his symptoms.
“The LIVE procedure is clearly less invasive and provides an important sense of control when operating on the beating heart.”
